Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
J Cutan Pathol. 2020 Jul;47(7):654-658. doi: 10.1111/cup.13673. Epub 2020 Mar 13.
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. This report is the first known case of DI-SCLE with positive anti-Ro antibodies in this setting. We also summarize the literature describing DI-SCLE in association with targeted therapies to date and its possible association with dysregulation of the vascular endothelial growth factor pathway.
药物诱导的亚急性皮肤型狼疮（DI-SCLE）是一种不常见但已有充分描述的现象，最常与抗高血压药和抗真菌药物有关。近年来，在接受靶向治疗的患者中也有罕见的 DI-SCLE 报告。在此，我们描述了一例与帕博西尼和来曲唑治疗转移性乳腺癌相关的 DI-SCLE 病例。本报告是该背景下首例已知的抗 Ro 抗体阳性的 DI-SCLE 病例。我们还总结了迄今为止描述靶向治疗相关 DI-SCLE 的文献，并探讨了其与血管内皮生长因子通路失调的可能关联。
